Abstract 3541
Background
Cancer follow-up care continues to evolve to incorporate complex programs of supportive care to address long-term disease consequences. However, care may be prescriptive and fragmented, contributing to uncertainty among cancer survivors. As major stakeholders in follow-up care for cancer survivors, nurses are ideally positioned to ensure supportive care is person-centred and responsive to patients’ needs. We recently conducted a study to summarize the evidence related to cancer survivors’ preferences for supportive care and examine the ways in which these preferences are embedded in current guidelines and policies informing cancer survivorship care. This presentation discusses specific implications of these findings for oncology nursing.
Methods
Phase 1 of the study comprises an integrative review of the empirical literature regarding cancer survivors’ preferences for supportive care, with literature sourced from bibilographic databases and analysed according to principles of thematic analysis. In Phase 2, clinical practice guidelines and policy documents guiding supportive care in cancer survivorship are evaluated using content analysis methods to ascertain alignment with the findings of Phase 1. Finally, we conduct a critical analysis of the results through the lens of oncology nursing practice.
Results
Findings of the integrative review and content analysis of practice and policy guidelines highlight issues related to where and when supportive care is accessed and the types and features of supportive care services. Given that these gaps intersect with nursing practice, they serve as potential targets of knowledge translation activities. Impacts on survivors’ experiences are illustrated with exemplars derived from recent qualitative studies conducted in Canadian and Irish contexts.
Conclusions
As novel programs are developed to meet the needs of the growing population of cancer survivors, a consideration of survivors’ preferences is essential. We offer specific ways in which nursing practice and scholarship can be leveraged to ensure the translation of this knowledge into care, making visible the survivors’ voice in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract